Scancell (LON:SCLP) Reaches New 1-Year High – What’s Next?

Shares of Scancell Holdings plc (LON:SCLP) hit a new 52-week high during trading on Friday . The company traded as high as GBX 14 and last traded at GBX 13.45, with a volume of 5803640 shares trading hands. The stock had previously closed at GBX 13.25.

Scancell Price Performance

The stock has a market capitalization of £139.58 million, a P/E ratio of -24.45 and a beta of 0.35. The business’s 50 day simple moving average is GBX 11.75 and its two-hundred day simple moving average is GBX 10.53. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last posted its earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. As a group, sell-side analysts forecast that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.